Rascol O - Search Results

1

Treatment interventions for Parkinson's disease: an evidence based assessment.

Rascol O, Goetz C, Koller W, Poewe W, Sampaio C. Rascol O, et al. Lancet. 2002 May 4;359(9317):1589-98. doi: 10.1016/S0140-6736(02)08520-3. Lancet. 2002. PMID: 12047983 Review.

2

Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content?

Kastner A, Hirsch EC, Lejeune O, Javoy-Agid F, Rascol O, Agid Y. Kastner A, et al. Among authors: rascol o. J Neurochem. 1992 Sep;59(3):1080-9. doi: 10.1111/j.1471-4159.1992.tb08350.x. J Neurochem. 1992. PMID: 1494900

3

Parkinson's disease and weight loss: a study with anthropometric and nutritional assessment.

Durrieu G, LLau ME, Rascol O, Senard JM, Rascol A, Montastruc JL. Durrieu G, et al. Among authors: rascol a, rascol o. Clin Auton Res. 1992 Jun;2(3):153-7. doi: 10.1007/BF01818955. Clin Auton Res. 1992. PMID: 1498561

4

Supplementary and primary sensory motor area activity in Parkinson's disease. Regional cerebral blood flow changes during finger movements and effects of apomorphine.

Rascol O, Sabatini U, Chollet F, Celsis P, Montastruc JL, Marc-Vergnes JP, Rascol A. Rascol O, et al. Among authors: rascol a. Arch Neurol. 1992 Feb;49(2):144-8. doi: 10.1001/archneur.1992.00530260044017. Arch Neurol. 1992. PMID: 1736846

5

Sublingual apomorphine in Parkinson's disease: a clinical and pharmacokinetic study.

Montastruc JL, Rascol O, Senard JM, Gualano V, Bagheri H, Houin G, Lees A, Rascol A. Montastruc JL, et al. Among authors: rascol a, rascol o. Clin Neuropharmacol. 1991 Oct;14(5):432-7. doi: 10.1097/00002826-199110000-00007. Clin Neuropharmacol. 1991. PMID: 1742752

6

Apomorphine test in parkinsonian syndromes.

Rascol O, Senard JM, Rascol A, Montastruc JL. Rascol O, et al. Among authors: rascol a. Lancet. 1990 Aug 25;336(8713):518. doi: 10.1016/0140-6736(90)92079-w. Lancet. 1990. PMID: 1975034 No abstract available.

7

[Comparison of bromocriptine and levodopa as first line treatment of Parkinson's disease: results of a 3-year prospective randomized study].

Montastruc JL, Rascol O, Rascol A. Montastruc JL, et al. Among authors: rascol a, rascol o. Rev Neurol (Paris). 1990;146(2):144-7. Rev Neurol (Paris). 1990. PMID: 2181588 Clinical Trial. French.

8

CQA 206-291: a novel dopamine agonist in the treatment of Parkinson's disease.

Rascol O, Fabre N, Teräväinen H, Poewe W, Lücking C, Rinne U, Dupont E, Hirt D, Hoyer M, Lataste X. Rascol O, et al. Clin Neuropharmacol. 1990 Aug;13(4):303-11. Clin Neuropharmacol. 1990. PMID: 2208182 Clinical Trial.

9

Alpha 2-adrenergic sensitivity in Parkinson's disease.

Berlan M, Rascol O, Belin J, Moatti JP, Rascol A, Montastruc JL. Berlan M, et al. Among authors: rascol a, rascol o. Clin Neuropharmacol. 1989 Apr;12(2):138-44. doi: 10.1097/00002826-198904000-00010. Clin Neuropharmacol. 1989. PMID: 2541904 No abstract available.

10

A randomised controlled study of bromocriptine versus levodopa in previously untreated Parkinsonian patients: a 3 year follow-up.

Montastruc JL, Rascol O, Rascol A. Montastruc JL, et al. Among authors: rascol a, rascol o. J Neurol Neurosurg Psychiatry. 1989 Jun;52(6):773-5. doi: 10.1136/jnnp.52.6.773. J Neurol Neurosurg Psychiatry. 1989. PMID: 2664089 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results